| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 15 | 2025 | 943 | 3.920 |
Why?
|
| Cardiovascular Diseases | 17 | 2023 | 2076 | 3.610 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2024 | 117 | 3.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2025 | 744 | 2.910 |
Why?
|
| Heart Failure | 12 | 2024 | 2341 | 2.540 |
Why?
|
| Eicosapentaenoic Acid | 6 | 2020 | 81 | 2.520 |
Why?
|
| Stroke | 7 | 2023 | 1041 | 2.050 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2025 | 293 | 1.970 |
Why?
|
| Cholesterol, LDL | 6 | 2022 | 611 | 1.840 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 725 | 1.780 |
Why?
|
| Anticholesteremic Agents | 4 | 2022 | 240 | 1.480 |
Why?
|
| Troponin I | 3 | 2024 | 121 | 1.470 |
Why?
|
| Dyslipidemias | 3 | 2019 | 246 | 1.450 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2023 | 78 | 1.420 |
Why?
|
| Hypolipidemic Agents | 3 | 2025 | 194 | 1.310 |
Why?
|
| Coronary Disease | 3 | 2023 | 644 | 1.220 |
Why?
|
| Hypercholesterolemia | 4 | 2020 | 234 | 1.190 |
Why?
|
| Stents | 2 | 2025 | 775 | 1.160 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 86 | 1.140 |
Why?
|
| Inferior Wall Myocardial Infarction | 2 | 2018 | 8 | 1.140 |
Why?
|
| Lipids | 4 | 2019 | 567 | 1.090 |
Why?
|
| Coronary Angiography | 5 | 2024 | 459 | 1.080 |
Why?
|
| Coronary Artery Disease | 3 | 2025 | 863 | 1.040 |
Why?
|
| Electrocardiography | 4 | 2024 | 980 | 1.010 |
Why?
|
| Risk Factors | 22 | 2025 | 10901 | 0.970 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 993 | 0.970 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 1006 | 0.950 |
Why?
|
| Ultrasonography, Interventional | 2 | 2025 | 202 | 0.930 |
Why?
|
| Multiple Sclerosis | 7 | 2023 | 391 | 0.890 |
Why?
|
| Humans | 79 | 2025 | 130931 | 0.870 |
Why?
|
| Brain Ischemia | 2 | 2023 | 261 | 0.840 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 22 | 0.840 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 46 | 0.820 |
Why?
|
| Myocardium | 3 | 2018 | 884 | 0.810 |
Why?
|
| Aged | 28 | 2025 | 21134 | 0.800 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 216 | 0.780 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2023 | 21 | 0.770 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2020 | 59 | 0.760 |
Why?
|
| Dietary Supplements | 3 | 2021 | 448 | 0.740 |
Why?
|
| Risk Assessment | 8 | 2025 | 3675 | 0.720 |
Why?
|
| Galectin 3 | 1 | 2021 | 31 | 0.690 |
Why?
|
| Biomarkers | 9 | 2024 | 3365 | 0.680 |
Why?
|
| Cardiology | 3 | 2021 | 505 | 0.680 |
Why?
|
| Lipid Regulating Agents | 1 | 2020 | 6 | 0.670 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2023 | 325 | 0.660 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2020 | 3 | 0.660 |
Why?
|
| Vascular Stiffness | 1 | 2021 | 83 | 0.650 |
Why?
|
| Denervation | 1 | 2020 | 25 | 0.650 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 1248 | 0.650 |
Why?
|
| Drug Monitoring | 2 | 2021 | 282 | 0.640 |
Why?
|
| Veterans | 3 | 2021 | 1781 | 0.630 |
Why?
|
| Middle Aged | 25 | 2025 | 28735 | 0.610 |
Why?
|
| Troponin T | 4 | 2024 | 252 | 0.590 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 3833 | 0.590 |
Why?
|
| Eligibility Determination | 1 | 2019 | 36 | 0.590 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 120 | 0.590 |
Why?
|
| Drug Costs | 1 | 2019 | 62 | 0.580 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 39 | 0.580 |
Why?
|
| Smoking Cessation | 1 | 2020 | 190 | 0.570 |
Why?
|
| Docosahexaenoic Acids | 1 | 2019 | 65 | 0.570 |
Why?
|
| Biological Products | 1 | 2020 | 144 | 0.560 |
Why?
|
| Anticoagulants | 3 | 2020 | 589 | 0.550 |
Why?
|
| Incretins | 1 | 2018 | 26 | 0.540 |
Why?
|
| Secondary Prevention | 1 | 2019 | 220 | 0.540 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 136 | 0.540 |
Why?
|
| Treatment Outcome | 12 | 2025 | 12858 | 0.540 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 376 | 0.530 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 884 | 0.530 |
Why?
|
| Cardiovascular System | 1 | 2018 | 103 | 0.520 |
Why?
|
| Pyrimidines | 1 | 2020 | 437 | 0.510 |
Why?
|
| United States | 16 | 2022 | 11718 | 0.500 |
Why?
|
| Kidney | 2 | 2020 | 1300 | 0.490 |
Why?
|
| Male | 33 | 2025 | 64823 | 0.480 |
Why?
|
| Proprotein Convertase 9 | 3 | 2022 | 110 | 0.460 |
Why?
|
| Genome-Wide Association Study | 6 | 2022 | 1834 | 0.450 |
Why?
|
| Hypertension | 2 | 2021 | 1357 | 0.450 |
Why?
|
| Peptide Fragments | 3 | 2023 | 776 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2023 | 569 | 0.440 |
Why?
|
| Ezetimibe | 3 | 2019 | 94 | 0.440 |
Why?
|
| Female | 30 | 2025 | 70755 | 0.440 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 466 | 0.420 |
Why?
|
| Aged, 80 and over | 9 | 2023 | 6862 | 0.410 |
Why?
|
| Hospitalization | 2 | 2019 | 1925 | 0.400 |
Why?
|
| Blood Pressure | 3 | 2024 | 1352 | 0.380 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2023 | 48 | 0.380 |
Why?
|
| Sitosterols | 2 | 2009 | 10 | 0.360 |
Why?
|
| Berberine | 2 | 2009 | 9 | 0.360 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2021 | 705 | 0.360 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 101 | 0.350 |
Why?
|
| Glucosides | 3 | 2020 | 53 | 0.340 |
Why?
|
| Tobacco, Smokeless | 2 | 2020 | 10 | 0.330 |
Why?
|
| Benzhydryl Compounds | 3 | 2020 | 76 | 0.330 |
Why?
|
| Dicarboxylic Acids | 3 | 2019 | 36 | 0.330 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 1134 | 0.320 |
Why?
|
| Prognosis | 6 | 2025 | 4930 | 0.310 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3067 | 0.310 |
Why?
|
| Europe | 2 | 2020 | 371 | 0.300 |
Why?
|
| Congresses as Topic | 2 | 2020 | 184 | 0.290 |
Why?
|
| Cholesterol | 2 | 2009 | 543 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1408 | 0.280 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 84 | 0.280 |
Why?
|
| Triglycerides | 3 | 2022 | 607 | 0.280 |
Why?
|
| Fatty Acids | 3 | 2019 | 361 | 0.280 |
Why?
|
| Phytosterols | 1 | 2008 | 28 | 0.280 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 310 | 0.270 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 2287 | 0.270 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 666 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2021 | 2849 | 0.240 |
Why?
|
| Heart Rate | 2 | 2018 | 578 | 0.230 |
Why?
|
| Time Factors | 4 | 2025 | 6275 | 0.230 |
Why?
|
| Mutation | 1 | 2018 | 6144 | 0.210 |
Why?
|
| Angiopoietin-like Proteins | 2 | 2022 | 15 | 0.210 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3799 | 0.210 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 170 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 2 | 2018 | 169 | 0.200 |
Why?
|
| Fishes | 1 | 2023 | 32 | 0.200 |
Why?
|
| Biological Phenomena | 1 | 2023 | 3 | 0.200 |
Why?
|
| Interleukin-18 | 1 | 2023 | 77 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 1164 | 0.200 |
Why?
|
| Postmenopause | 2 | 2020 | 149 | 0.200 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 549 | 0.200 |
Why?
|
| HLA-DRB1 Chains | 2 | 2013 | 47 | 0.190 |
Why?
|
| Animals | 8 | 2023 | 34278 | 0.190 |
Why?
|
| HLA-B Antigens | 2 | 2012 | 30 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2023 | 6443 | 0.180 |
Why?
|
| Adult | 14 | 2025 | 31541 | 0.180 |
Why?
|
| Phenotype | 4 | 2021 | 4493 | 0.180 |
Why?
|
| Radial Artery | 1 | 2022 | 34 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2023 | 415 | 0.180 |
Why?
|
| HLA Antigens | 2 | 2021 | 226 | 0.170 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 53 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 1395 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 448 | 0.170 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.170 |
Why?
|
| Tobacco Use | 1 | 2020 | 31 | 0.170 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2020 | 49 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 162 | 0.170 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 31 | 0.170 |
Why?
|
| Telecommunications | 1 | 2020 | 21 | 0.170 |
Why?
|
| Vitamin K | 1 | 2020 | 35 | 0.160 |
Why?
|
| Behavioral Risk Factor Surveillance System | 4 | 2021 | 51 | 0.160 |
Why?
|
| Oligonucleotides | 1 | 2020 | 96 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 105 | 0.160 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 48 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 73 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2020 | 61 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2019 | 392 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 455 | 0.160 |
Why?
|
| Multidetector Computed Tomography | 1 | 2019 | 33 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 80 | 0.160 |
Why?
|
| Vaping | 1 | 2020 | 31 | 0.160 |
Why?
|
| Echocardiography | 2 | 2023 | 1135 | 0.160 |
Why?
|
| Protective Factors | 1 | 2020 | 90 | 0.160 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 55 | 0.150 |
Why?
|
| Angina Pectoris | 1 | 2019 | 58 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 76 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2019 | 41 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 130 | 0.150 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 28 | 0.150 |
Why?
|
| Heart Ventricles | 2 | 2021 | 772 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 160 | 0.150 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.150 |
Why?
|
| Schizophrenia | 1 | 2022 | 330 | 0.150 |
Why?
|
| RNAi Therapeutics | 1 | 2019 | 17 | 0.150 |
Why?
|
| Office Visits | 1 | 2019 | 81 | 0.150 |
Why?
|
| Heart Transplantation | 1 | 2025 | 873 | 0.150 |
Why?
|
| RNA Interference | 1 | 2020 | 497 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 310 | 0.140 |
Why?
|
| Bipolar Disorder | 1 | 2022 | 363 | 0.140 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2018 | 20 | 0.140 |
Why?
|
| Monocytes | 1 | 2020 | 334 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2020 | 199 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 214 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 298 | 0.140 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 47 | 0.140 |
Why?
|
| Paraplegia | 1 | 2018 | 88 | 0.140 |
Why?
|
| Young Adult | 4 | 2020 | 10040 | 0.140 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 125 | 0.140 |
Why?
|
| Cysts | 1 | 2018 | 94 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 229 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1625 | 0.130 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 117 | 0.130 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2017 | 44 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 358 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 373 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 172 | 0.130 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 185 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 545 | 0.130 |
Why?
|
| Cause of Death | 1 | 2019 | 507 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 156 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2019 | 829 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 1233 | 0.120 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2017 | 110 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 241 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 788 | 0.120 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 19 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 642 | 0.120 |
Why?
|
| Genotype | 2 | 2021 | 2651 | 0.120 |
Why?
|
| Incidence | 2 | 2025 | 3327 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 333 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 505 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 506 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 20814 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 463 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 2020 | 539 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 492 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2019 | 530 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 232 | 0.120 |
Why?
|
| Action Potentials | 1 | 2018 | 471 | 0.110 |
Why?
|
| Patient Selection | 1 | 2019 | 724 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 275 | 0.110 |
Why?
|
| Recurrence | 3 | 2023 | 1473 | 0.110 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 213 | 0.110 |
Why?
|
| Testosterone | 1 | 2020 | 603 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 679 | 0.110 |
Why?
|
| Macular Degeneration | 1 | 2016 | 91 | 0.110 |
Why?
|
| Aging | 1 | 2022 | 1257 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2018 | 861 | 0.110 |
Why?
|
| Lipoproteins | 2 | 2022 | 183 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1157 | 0.100 |
Why?
|
| Alleles | 2 | 2021 | 1705 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 32 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2020 | 703 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2018 | 1611 | 0.090 |
Why?
|
| HLA-DP beta-Chains | 1 | 2012 | 10 | 0.090 |
Why?
|
| Major Histocompatibility Complex | 1 | 2012 | 55 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2018 | 5096 | 0.090 |
Why?
|
| Genome, Human | 3 | 2021 | 1331 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2016 | 925 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5257 | 0.080 |
Why?
|
| Population Groups | 1 | 2010 | 31 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 410 | 0.080 |
Why?
|
| Amino Acids | 1 | 2013 | 620 | 0.080 |
Why?
|
| Immunologic Factors | 2 | 2022 | 191 | 0.080 |
Why?
|
| Prevalence | 3 | 2022 | 2681 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2017 | 3433 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 33 | 0.080 |
Why?
|
| Brain | 2 | 2022 | 3161 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 830 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 33 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 3397 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 45 | 0.080 |
Why?
|
| Child | 2 | 2020 | 26098 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 477 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2012 | 284 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1084 | 0.070 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 14 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 418 | 0.070 |
Why?
|
| Disease Progression | 2 | 2023 | 2191 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4681 | 0.060 |
Why?
|
| Age Factors | 2 | 2025 | 2866 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 1587 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2018 | 4645 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1559 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1145 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 1022 | 0.060 |
Why?
|
| Allografts | 1 | 2025 | 204 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17485 | 0.060 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 11 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 631 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2023 | 43 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 14945 | 0.050 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2022 | 22 | 0.050 |
Why?
|
| Apolipoprotein C-III | 1 | 2022 | 46 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 3457 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 102 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 46 | 0.040 |
Why?
|
| Atrophy | 1 | 2022 | 245 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 357 | 0.040 |
Why?
|
| Haplotypes | 2 | 2013 | 543 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 4008 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 49 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 119 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2023 | 768 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 201 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 175 | 0.040 |
Why?
|
| Acute Disease | 1 | 2023 | 1153 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 14 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2031 | 0.040 |
Why?
|
| Amlodipine | 1 | 2019 | 21 | 0.040 |
Why?
|
| Lisinopril | 1 | 2019 | 27 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2019 | 64 | 0.040 |
Why?
|
| Metoprolol | 1 | 2019 | 21 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 78 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 674 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 72 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 365 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 486 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 531 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2020 | 289 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 586 | 0.030 |
Why?
|
| Exome | 1 | 2022 | 1073 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2017 | 130 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 297 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 275 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2017 | 174 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 726 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 660 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1344 | 0.030 |
Why?
|
| Metagenomics | 1 | 2017 | 114 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 421 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 405 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 794 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 272 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1565 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 319 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1705 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1094 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 109 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2950 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2965 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2013 | 200 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 271 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 865 | 0.020 |
Why?
|
| Disease Resistance | 1 | 2012 | 21 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2013 | 185 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1202 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 749 | 0.020 |
Why?
|
| Mice | 2 | 2018 | 18410 | 0.020 |
Why?
|
| Human Genome Project | 1 | 2010 | 55 | 0.020 |
Why?
|
| Absorption | 1 | 2009 | 50 | 0.020 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2009 | 13 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 834 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 367 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2009 | 106 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 237 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 435 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 191 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 227 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2009 | 286 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1009 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 1500 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1790 | 0.010 |
Why?
|